Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.59 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.59 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.59 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | PYGB | P11216 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | OGA | O60502 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15314105 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL19317500 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL4439225 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL24115372 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL13632537 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL24243426 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL17931796 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL13197776 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL5452134 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL5444372 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10588962-B2 | Carbohydrate-glycolipid conjugate vaccines | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-03-17 | — | — | US | disclosed |
| US-20090156841-A1 | CONVERSION OF CARBOHYDRATES TO HYDROXYMETHYLFURFURAL (HMF) AND DERIVATIVES | ARCHER DANIELS MIDLAND CO. | 2009-06-18 | — | — | US | disclosed |
| US-20070155971-A1 | Chiral diphosphorus compounds and their transition metal complexes | Source Global, PBC | 2007-07-05 | — | — | US | disclosed |
| US-7193092-B2 | Chiral diphosphorus compounds and their transition metal complexes | LANXESS DEUTSCHLAND GMBH (DE) | 2007-03-20 | — | — | US | disclosed |
| EP-1400527-B1 | Chiral diphosphorus compounds and transition metal complexes thereof | LANXESS DEUTSCHLAND GMBH (DE) | 2006-03-22 | — | — | EP | disclosed |
| EP-1398319-B1 | Chiral monophosphorus compounds and transition metal complexes thereof | LANXESS DEUTSCHLAND GMBH (DE) | 2005-11-09 | — | — | EP | disclosed |
| US-20050080047-A1 | Chiral diphosphorus compounds and their transition metal complexes | LANXESS DEUTSCHLAND GMBH (DE) | 2005-04-14 | — | — | US | disclosed |
| US-20040127430-A1 | Chiral monophosphorus compounds and their transition metal complexes | LANXESS DEUTSCHLAND GMBH (DE) | 2004-07-01 | — | — | US | disclosed |
| EP-1400527-A1 | Chiral diphosphorus compounds and transition metal complexes thereof | Bayer Chemicals AG (DE) | 2004-03-24 | — | — | EP | disclosed |
| EP-1398319-A1 | Chiral monophosphorus compounds and transition metal complexes thereof | Bayer Chemicals AG (DE) | 2004-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127430-A1 | Chiral monophosphorus compounds and their transition metal complexes | MDM4, MPHOSPH6, AP3M1 | LGALS1 2383/4885LGALS3 1346/4885LGALS9 1799/4885 |
| US-20090156841-A1 | CONVERSION OF CARBOHYDRATES TO HYDROXYMETHYLFURFURAL (HMF) AND DERIVATIVES | HPD, FOS, MCCC2 | LGALS1 1370/4885LGALS3 1627/4885LGALS9 891/4885 |
| US-20070155971-A1 | Chiral diphosphorus compounds and their transition metal complexes | CDIPT, DCPS, PIN1 | LGALS1 2769/4885LGALS3 1935/4885LGALS9 2158/4885 |
| US-20050080047-A1 | Chiral diphosphorus compounds and their transition metal complexes | CDIPT, DCPS, PIN1 | LGALS1 2769/4885LGALS3 1935/4885LGALS9 2158/4885 |
| US-10588962-B2 | Carbohydrate-glycolipid conjugate vaccines | STT3B, STT3A, DDOST | LGALS1 176/4885LGALS3 119/4885LGALS9 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.